Clinical trial summary of agalsidase alfa in kidney dysfunction in Fabry disease
Melissa West, Bruce A. Barshop(University of California San Diego), Archi Mehta, Robert W. Steiner, Kathy Nicholls(Melbourne Health), Ellen H. Boyd, William J. Rhead(Children's Hospital of Wisconsin), Markus Ries(Heidelberg University)
UCL Discovery (University College London)
January 1, 2009
Cited by 0
Related Papers
Metabolomics Reveals Signature of Mitochondrial Dysfunction in Diabetic Kidney Disease
|Journal of the American Society of Nephrology|2013|578
Treatment of Fabry’s Disease with the Pharmacologic Chaperone Migalastat
|New England Journal of Medicine|2016|555
Survival after Treatment with Phenylacetate and Benzoate for Urea-Cycle Disorders
|New England Journal of Medicine|2007|357
Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy
|JAMA|2022|342
Targeted disruption of mouse long-chain acyl-CoA dehydrogenase gene reveals crucial roles for fatty acid oxidation
|Proceedings of the National Academy of Sciences|1998|254